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1. Introduction 
Reduction or oxidation caused by addition or loss of any electron is responsible for 
alterations in functional and structural profile of molecules, hence, changing signaling 
mechanism. Reactive free radicals play a crucial role in different physiological mechanisms 
ranging from the immune defense to cell signaling and inflammation (Elahi & Matata, 2006). 
There is increasing evidence that irregular production of free radicals lead to enhanced 
stress on cellular structures and causes changes in molecular pathways that underpins the 
pathogenesis of several relevant human disorders, such as cancer, heart diseases, the process 
of physiological ageing and neurological diseases (Pacher & Szabo, 2008; Lushchak, 2011a; 
Lushchak, 2011b). Comprehending the involvement of free radical stress in the pathogenesis 
of disease will allow us to investigate the development of oxidative stress; a condition that 
occurs due to an imbalance between cellular production of oxidant molecules and the 
availability of appropriate antioxidants species that defend against them. It is hoped that 
this knowledge will subsequently lead to the development of effective therapeutic 
interventions against oxidative stress. 
The main molecules that are involved in redox signaling are called as reactive oxygen 
species (ROS), in which we may include hydrogen peroxide (H2O2), nitric oxide (NO), 
hydroxyl radical, superoxide (O2−) and peroxynitrite. Current redox signaling 
investigations indicate that all the vascular constituents, including vascular smooth muscle 
cells (VSMCs), endothelial and adventitial cells and macrophages, produce ROS 
(Papaharalambus & Griendling, 2007). ROS are involved in signal transduction which is 
related to relaxation and contraction of blood vessels, migration, growth and death of 
vascular cells, and also extracellular matrix (ECM) alterations. 
It is known that vascular diseases such as peripheral vascular disease, coronary artery 
disease and cerebrovascular diseases are the largest cause of morbidity and mortality in 
industrialized countries. Some common risk factors for vascular disease, including diabetes 
and hypertension are still prevalent in Western and other populations, indicating that 
vascular disease will possible continue to impose a substantial burden on health care 
resources throughout the next generation. The earliest detectable changes in vascular 
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disease states are irregularities of the endothelium, resulting in loss of the endothelium’s 
normal homeostatic functions that normally act to inhibit disease-related mechanisms such 
as thrombosis and inflammation. Particularly, it was previously demonstrated that nitric 
oxide (NO) produced by NO synthase (eNOS) in the vascular endothelium modulates blood 
flow and pressure and presents important antiatherogenic effects on platelets, vascular 
smooth muscle and endothelial cells (Umans and Levi, 1995). 
Many previous studies have already demonstrated the effects of oxidative stress on the 
cardiovascular system. Superoxide dismutase (SOD), an enzyme that catalyze the 
dismutation of O2− into oxygen and H2O2,  injected into brainstem areas involved in 
cardiovascular regulation decreased sympathetic nerve activity and decreased blood 
pressure in swine (Zanzinger and Czachurski, 2009). According to Campese et al. (2004) the 
lack of low-density lipoprotein (LDL) receptor-enhanced cholesterol blood levels enhanced 
ROS and impared baroceptor reflex function. Monahan et al (2004) indicated that oxidative 
stress collaborates to age-associated decreases in cardiovagal baroreflex sensitivity in 
healthy subjects. Conversely, it was indicated in male smokers that circulating antioxidants 
had no effect on baroceptor reflex, and minor effects on the cardiovascular system were seen 
following acute fat and vitamin ingestion (Wright et al, 2009). Overall, comprehending the 
process which redox signaling modulates cardiovascular system will provide further precise 
ROS regulation as a therapy for cardiovascular disorders. In this chapter we summarize 
concepts regarding oxidative stress related to cardiovascular disorders.  
2. Models of ROS-induced cardiovascular diseases 
Basic science applied in animal is indispensable to comprehend the pathogenesis, 
mechanisms involved in therapeutic agents, molecular process, and environmental or 
genetic factors that increases the risks of disease development. The species of animal studied 
are influenced by numerous aspects. Usually, animals with small size are preferred because 
they are more manageable and experiments are less expensive. According to the guide of 
the principles of animal research, we should use the lowest possible animal and, nowadays, 
permission would not be granted for using larger animals unless a similar experiment could 
not be performed on rodent. Nevertheless, a major criticism of using rodents is that they 
may not adequately correspond to the human situation and this fact occasionally justifies 
the use of larger animals such as pigs and monkeys (Rees & Alcolado, 2005). In this topic we 
described the main animal models used in the literature to investigate the mechanisms 
involved in ROS-induced cardiovascular disorders. 
The relationship between enhanced ROS and hypertension is well established in many 
studies involving diet or endocrine-induced and surgically-induced hypertensive animals 
(Banday et al, 2007). A variety of evidence suggests that ROS collaborate to impaired 
endothelial function in several forms of hypertension and that there is enhanced ROS in the 
microvessels of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive hypertensive 
rats (Manning et al, 2003). An interesting study by Lenda et al (2000) suggested that ROS can 
also collaborate to a decreased endothelium-dependent dilation in normotensive rats under 
an enhanced salt diet. Although the latent level of ROS in contributing to damaged 
endothelium-dependent vasodilation and decreased NO production during increased 
dietary salt intake, the nature and mechanisms of the impaired vascular relaxation with the 
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high-salt diet and the role of enhanced ROS in contributing to salt-induced changes in 
vascular function and hypertension are not completely understood (Cai & Harrison, 2000). 
Hypertension is a result of enhanced ROS, however, data regarding the most potent cause of 
ROS-induced hypertension is controversial. In fact, oxidative stress does not elucidate the 
cause of every kind of hypertension, which develops through many processes. A small 
number of clinical investigations indicated the protective property of antioxidants (Ceriello 
et al, 1991; Galley et al, 1997). Nevertheless, it is known that not all animal models of 
hypertension are related to ROS (Rajagopalan et al, 1996). Additionally, clinical studies 
demonstrated negative correlation between arterial pressure and oxidative stress markers in 
subjects with mild to moderate hypertension (Cracowski et al, 2003). It is hard to find a 
cause–effect association between hypertension and oxidative stress in clinical studies, 
however, some studies indicated that increased ROS is a risk factor for human hypertension 
(Adbilla et al, 2007). 
Animal models are important to support the link between hypertension and oxidative 
stress. Some procedures performed in animal models helped to comprehend the 
mechanisms involved in ROS-induced hypertension (Rajagopalan et al, 1996; Puzserova et 
al, 2010; Valenti et al, 2011a).   
The group of Zucker and coworkers from Nebraska have used a model based on heart 
failure in rabbits (Mousa et al, 2008). According to their method, a platinum wire pacing 
electrode is sutured to the epicardium of the left ventricle in the rabbits. A ground electrode 
is secured to the left atrium. All wires are tunneled beneath the skin and exited in the 
midscapular area. The chest is closed and evacuated; in the same setting, a radiotelemetry 
unit is implanted into the right femoral artery with the tip of its catheter in the descending 
aorta to monitor blood pressure and heart rate in the conscious state. Rabbits were allowed 
to recover from surgery for two weeks before they were used in the study. They developed a 
rapid pacing model of chronic heart failure. After recovery from surgery, animals are paced 
at a rate of 360–380 beats/min with the use of a small, light-weight pacing unit of their own 
design. The pacing rate is adjusted and monitored by frequent echocardiograms. In general, 
each rabbit is paced at 360 beats/minute for the first week to determine whether it would 
tolerate this protocol. After the first week, the pacing rate is enhanced to 380 beats/minute 
and continued at this rate for the remainder of the protocol. The rabbits are continuously 
paced for 3 weeks. Cardiac dimensions (left ventricular end-diastolic diameter, left 
ventricular end-systolic diameter, fractional shortening, and ejection fraction) and other 
hemodynamic parameters are monitored on a weekly basis. Additionally, to left ventricular 
dimension changes, clinical signs of chronic heart failure such as ascites, pulmonary 
congestion, and cachexia are appreciated as symptoms of this chronic heart failure model. 
This model is well accepted in the literature and it was observed enhanced production of 
ROS in the heart and in the brainstem. Furthermore, they measured two of the three major 
SOD isoforms (Cu,Zn-SOD and Mn-SOD) and the catalytic subunit of NAD(P)H oxidase, 
gp91phox into the brainstem. They reported that protein expression of both CuZn SOD and 
Mn SOD was significantly downregulated in the chronic heart failure condition. The 
gp91phox protein was significantly enhanced in chronic heart failure rabbits (Gao et al, 
2007). The more affected area was the rostroventrolateral area of the medulla oblongata.  
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The renovascular model of hypertension is a model which presented enhanced level of ROS 
(Campos et al, 2011). In this model, rats are anesthetized with ketamine and xylazine (40 mg 
and 10 mg/kg, respectively, ip); the left renal artery is exposed through an abdominal 
incision, and the renal artery and renal vein are dissected free from the adherent tissues. The 
left renal artery is partially obstructed with a silver clip of 0.2-mm width. No clip 
obstruction is applied to the sham-operated group (n = 15). Animals are submitted to the 
final experimental procedures 3 or 6 weeks after the surgical procedure. Systolic blood 
pressure is measured in conscious rats using a pneumatic tail-cuff method.  
The role of ROS has been shown in this model of ROS-induced cardiovascular injury, in 
which the chronic administration of a SOD mimetic, tempol, to reduce ROS was shown to 
reduce blood pressure (Welch et al, 2003). Moreover, tempol was more effective than AT1 
antagonist (candesartan) in reducing blood pressure and in improving renal function in 
renovascular hypertensive rats, suggesting that ROS plays an important role in mediating of 
renovascular hypertension (Palm et al, 2010). However, besides the actions of ROS on many 
tissues, the brain is one of the Ang II targets most affected by ROS. Even when an increase in 
plasma renin activity is modest after moderate renal artery stenosis, ROS remains increased 
and collaborates to hypertension (Lerman et al, 1991).Therefore, the involvement of Ang II is 
believed to decline, whereas ROS increases, during the progression of the 2K1C model. Our 
hypothesis is that even with a modest increase in circulating Ang II, this peptide acting in 
the CNS through AT1 receptors might collaborate to NADPH activation, which leads to an 
increase in local ROS production, causing sympathoexcitation and arterial hypertension. 
The central regulation of the sympathetic nervous system (SNS) involved in cardiovascular 
regulation is complex, involving multiple reflex pathways and neural connections with a 
large number of neurotransmitters and neuromodulators acting in specific groups of 
neurons in the CNS involved in the tonic and reflex control of the cardiovascular system. In 
the CNS, Ang II is able to increase sympathetic vasomotor tone and blood pressure, and is 
involved in the pathogenesis of many experimental models of hypertension (Campos, 2009). 
Therefore, the close functional association between NADPH oxidase and the Ang II is of 
particular relevance in linking oxidative stress in the brain to sympathoexcitation and 
hypertension. For instance, intracerebroventricular infusion of NADPH oxidase inhibitor 
antagonizes the pressor response induced by centrally mediated Ang II actions (Gao et al, 
2007). In the brain, the overexpression of SOD, an enzyme responsible for O2− breakdown, 
also abolishes the central pressor effect of the octapeptide, suggesting that in the CNS there 
is a positive correlation between the increase in ROS and the central pressor response 
mediated by Ang II (Zimmerman et al, 2004). Considering that the paraventricular nucleus 
of the hypothalamus (PVN) and the rostroventrolateral medulla (RVLM) contain critically 
important neurons involved in the control of sympathetic vasomotor tone and arterial 
pressure (Valenti et al, 2011a), in the studies reviewed in this article it was examined an 
increase in AT1 receptor expression and oxidative stress markers within these two nuclei in 
renovascular hypertension. NAD(P)H oxidase subunits (p47phox and gp91phox) and anti-
oxidant enzyme CuZnSOD mRNA expression were quantified in the RVLM and PVN of 
renovascular hypertensive rats. It was hypothesized that the overactivity of NADPH 
oxidase-derived ROS associated with a reduction in the activity of CuZnSOD within the 
RVLM and PVN could collaborate to renovascular hypertension, particularly in the renin-
dependent phase of hypertension. 
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In hypertensive renovascular rats, there is a significant increase in systemic ROS, estimated 
by the thiobarbituric acid reactive substance (TBARS) level in plasma, compared with 
control rats. Administration of tempol or Vitamin C systemically decreased blood pressure 
and RSNA only in renovascular hypertensive rats, indicating that the depressor effect in 
response to the anti-oxidant administration is mediated by a reduction in sympathetic 
vasomotor activity (Oliveira-Sales et al, 2008). 
Some studies evaluated the effects of ROS on vascular properties in rat aorta (Toba et al, 
2010; Olukman et al, 2010). Others tried to reveal the mechanisms involved in ROS-induced 
cardiovascular disease inside the brainstem (Zanzinger et al, 2009; Valenti et al, 2011a; 
Campos et al, 2011).  
The SHR is a model which has been well investigated (He et al, 2011). SHR and stroke-prone 
SHR (SPSHR), genetic models that develop hypertension spontaneously, exhibit enhanced 
NAD(P)H driven O2− generation in resistance (mesenteric) and conduit (aortic) vessels 
(Rodriguez-Iturbe et al, 2003). This is associated with NAD(P)H oxidase subunit 
overexpression and enhanced oxidase activity (Kishi et al, 2004). Several polymorphisms in 
the promoter region of the p22phox gene have been identified in SHR (Zalba et al, 2001). 
This has clinical relevance because an association between a p22phox gene polymorphism 
and NAD(P)H oxidase–mediated O2− production in the vascular wall of patients with 
hypertension and atherosclerosis has been described (Moreno et al, 2003).  
Enhanced expression of p47phox has been reported in the renal vasculature, macula densa, 
and distal nephron from young SHR, suggesting that renal NAD(P)H oxidase upregulation 
precedes development of hypertension (Kishi et al, 2004). Diminished nitric oxide 
bioavailability as a consequence of enhanced vascular O2− generation and downregulation of 
the thioredoxin system may also collaborate to oxidative stress in SHR and SPSHR (Touyz 
2003). Treatment with antioxidant vitamins, NAD(P)H oxidase inhibitors, SOD mimetics, and 
BH4 and Ang II type-1 (AT1) receptor blockers decrease vascular O2− production and 
attenuate development of hypertension in these models (Rodriguez-Iturbe et al, 2003; Shokoji 
et al, 2003). Taken together, these findings suggest that oxidative stress in genetic hypertension 
involves enhanced NAD(P)H oxidase activity and dysfunctional endothelial nitric oxide 
synthase (uncoupled NOS) and is regulated, in part, by AT1 receptors. Figure 1 presents a 
surgical procedure to record mean arterial pressure and heart rate, while Figure 2 shows 
recordings from one normotensive Wistar Kyoto and one SHR rat illustrating reflex 
bradycardia (top) in response to blood pressure increases. In this Figure we may observe the 
enhanced mean arterial pressure of the SHR compared to the control animal. 
In animal models of diabetes, several functional and structural alterations of the heart or in 
cardiac muscle have been documented (Russel et al, 2006). In most studies of type 1 diabetes 
mellitus, diabetes are induced after administration of the pancreatic beta-cell toxin 
streptozotocin, and most studies of type 2 diabetes mellitus have been performed in genetic 
models of obesity and insulin resistance such as the Zucker fatty rat or db/db mice, both of 
which have mutations that impair leptin receptor signaling, or ob/ob mice, which lacks 
leptin. Furthermore, because diabetes mellitus develops at varying tempos in these models, 
it is important to bear in mind that studies performed in animals before the onset of diabetes 
may reflect changes that are secondary to the underlying obesity and insulin resistance, and  
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Fig. 1. Surgical procedure to record basal mean arterial pressure and heart rate in one 
spontaneously hypertensive rat. 
studies performed after the onset of diabetes may reflect the added effects of hyperglycemia 
of various durations. Most studies have been performed in isolated perfused hearts and 
reveal depressed cardiac function (Aasum et al, 2002; Aasum et al, 2003). In vivo studies in 
these rodent models have provided evidence for systolic and diastolic dysfunction by 
echocardiography (Christoffersen et al, 2003) but in some studies using invasive left 
ventricle catheterization in mouse models of obesity and diabetes mellitus, left ventricle 
contractility as determined by developed pressure/developed tension was initially 
enhanced and may reflect the impact of the enhanced plasma volume and perhaps 
sympathetic activation associated in part with the underlying obesity (Buchanan et al, 2005). 
These first observations were additionally clarified later (Van den Bergh et al, 2006). It was 
assessed the hemodynamic changes in db/db mouse hearts in vivo using a pressure–
volume instrument. It was reported decreased contractility using load-independent 
variables such as preload recruitable stroke work, but steady-state measurements of cardiac 
output and other load-dependent parameters were increased in db/db mice compared with 
control mice because of favorable loading conditions, specifically enhanced preload and 
decreased afterload. 
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Fig. 2. Recordings from one Wistar Kyoto control rat and one spontaneously hypertensive 
rat illustrating reflex bradycardia (top) in response to blood pressure increases. Infusions 
were given in bolus. MAP: mean arterial pressure; PAP: pulsatile arterial pressure; HR: 
heart rate; PHE: phenylephrine. 
Enhanced ROS production in the diabetic heart is a contributing matter to the progression 
and the development of diabetic cardiomyopathy (Cai et al, 2006). Cumulative superoxide-
mediated damage or cellular dysfunction results when an imbalance exists in ROS 
generation and ROS-degrading pathways. Enhanced ROS generation and impaired 
antioxidant defenses could both collaborate to oxidative stress in diabetic hearts. Several 
groups have shown that ROS is overproduced in both type 1 and type 2 diabetes (Cai et al, 
2006). Under physiological states, most of the ROS generated within cells arises from 
mitochondria. Whereas enhanced mitochondrial ROS generation has been shown in various 
tissues such as endothelial cells that are exposed to hyperglycemia (Brownlee, 1995), 
relatively few studies to date have directly measured mitochondrial ROS production in 
mitochondria obtained from diabetic hearts. However, overexpression of mitochondrial 
superoxide dismutase (SOD2) in the heart of a mouse model of type 1 diabetes mellitus 
reversed altered mitochondrial morphology and function and maintained cardiomyocyte 
function (Shen et al, 2006). Evidence also exists for enhanced production of ROS from non 
mitochondrial sources such as NADPH oxidase or decreased neuronal nitric oxide synthase 
(NOS1) activity coupled with enhanced activation of xanthine oxidoreductase (Saraiva et al, 
2006). Whereas evidence for enhanced ROS production in diabetes mellitus is reasonably 
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strong, the effect of diabetes on antioxidant defenses in the heart is controversial. Thus, the 
activities/expression levels of glutathione peroxidase, copper/zinc SOD, or catalase were 
either enhanced (Li et al, 2006) or decreased (Matkovics et al, 1997). Enhanced ROS 
generation may activate maladaptive signaling pathways, which may lead to cell death, 
which could collaborate to the pathogenesis of diabetic cardiomyopathy. Enhanced ROS 
production was associated with enhanced apoptosis, as evidenced by enhanced in situ nick 
end-labeling (TUNEL) staining and caspase 3 activation in ob/ob and db/db hearts 
(Barouch et al, 2003). In the same study, enhanced ROS was also associated with enhanced 
DNA impairment and loss of activity of DNA repair pathways that declined more rapidly 
with age in diabetic versus control animals.  
Therefore, enhanced ROS-modulated cell death is able to promote irregular cardiac 
remodeling, which ultimately may collaborate to the morphological characteristic and 
functional abnormalities that are associated with diabetic cardiomyopathy. In addition to 
causing cellular injury, enhanced ROS production might lead to cardiac dysfunction via 
other mechanisms. For instance, enhanced ROS has been proposed to amplify 
hyperglycemia-induced activation of protein kinase C isoforms, enhanced formation of 
glucose-derived advanced glycation end products, and enhanced glucose flux through the 
aldose reductase pathways (Brownlee et al, 1995), which may all collaborate to various ways 
to the development of cardiac complications in diabetes mellitus.  Enhanced ROS also might 
collaborate to mitochondrial uncoupling, which could impair myocardial energetic 
metabolism in diabetes.  
Strategies that enhance mitochondrial ROS scavenging systems have been demonstrate to be 
effective in decreasing diabetes-induced cardiac dysfunction. Overexpression of 
metallothionein, catalase, and manganese SOD (Shen et al, 2006) in the heart reversed 
diabetic cardiomyopathy in animal models of both type 1 and type 2 diabetes. Therefore, 
strategies that either reduce ROS or augment myocardial antioxidant defense mechanisms 
might have therapeutic efficacy in improving myocardial function in diabetes mellitus. 
In summary, experimental protocols applied in animals are necessary to understand the 
pathological events involved in cardiovascular diseases development. However, there are 
differences between human and animals like rat and mouse. Thus, we should be careful 
when interpreting data aiming to apply in humans regarding processes related to 
therapeutic agents, molecular process, and environmental or genetic factors that enhances 
the risks for cardiovascular disorders development.  
3. Sources of ROS in cells 
The literature indicated that vascular cells, as well as cardiomyocytes and neurons, produce 
ROS, contributing to the development of disorders related to the cardiovascular system. 
Although several enzyme systems produce ROS, many of them are prevalent in pathologic 
processes. Among the main ROS generators we may include cytochrome P450, the 
mitochondrial respiratory chain, xanthine oxidase (XO), uncoupled endothelial nitric oxide 
synthase (eNOS), heme oxygenase, myeloperoxidase, lipoxygenase, cyclooxygenase and 
NADPH oxidases. Some of these systems have been proven to be relevant to hypertension 
(Lee & Griendling, 2008). 
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Others mechanisms involved in ROS production are better described in the chapters from 
this book. Thus, we will only briefly describe the main sources in this topic. 
Based on the literature, the NOX family includes seven members, which are NOX1-5 and 
DUOX1-2. NOX2 NADPH oxidase is the predominant source of ROS production in humans 
(Nauseef, 2004). The main sources of ROS are phagocytic cells—neutrophils and 
macrophages. NOX2-NADPH oxidase is formed by functional transmembrane 
heterodimers, gp91 phox and p22 phox (also known collectively as the cytochrome b558), 
and four regulatory cytosolic subunits—p40 phox , p47 phox , p67 phox , and the small 
GTPase, Rac2. In the dormant state, cytochrome b558 resides in intracellular vesicles, while 
cytosolic Rac2 remains inactive in the guanosine diphosphate (GDP) bound state via 
interaction with RhoGDI (Ando et al, 1992). Upon the initiation of phagocytosis, GDP-Rac2 
is converted to GTP-Rac2 through the activity of a Rac guanine nucleotide exchange factor. 
This allows for Rac2 translocation to the plasma or phagosomal membrane, thereby 
allowing the subsequent transit of cytochrome b558 from the vesicle to the membrane 
(Diebold and Bokoch, 2001). Concurrently, p47 phox is phosphorylated and undergoes a 
conformational change that now exposes two SRC-homology 3 regions to interact with the 
proline rich motif on p22 phox (Dusi et al, 1993). Furthermore, Phox homology domains on 
p47 phox allow for binding to phosphatidylinositol 3-phosphate (PI(3)P) and PI(3,4)P2, 
transient phosphoinositides that are generated only at the plasma membrane upon 
phagocytosis, thus, further stabilizing p47 phox localization to cytochrome b558 (Nauseef, 
2004). 
Among ROS sources, the NADPH oxidases are considered unique because from those 
components it is generated ROS in a highly regulated mode whereas ROS are generated as a 
by-product of enzymatic activity for all the other sources (Cave et al, 2006). Moreover, 
NADPH oxidases can stimulate further ROS production from one or more of the above 
enzymes, thereby being able to act as initiating sources of ROS. O2−radical is the first 
moiety that is generated by NADPH oxidases (or most of the other sources) and can be 
rapidly dismutated to H2O2. The biological effects of ROS are expected to depend on the 
specific moiety generated, its localization and the relative balance between levels generated 
and the activity of antioxidant mechanisms; most signaling effects of ROS are considered to 
be mediated by H2O2 which is more stable and diffusible than O2−. 
XO is another potential source for ROS in vasculature. XO is a form of xanthine 
oxidoreductase that occurs in two different forms. The predominant form, xanthine 
dehydrogenase (XDH), can be converted into XO reversibly by direct oxidation of critical 
cysteine residues or irreversibly by proteolysis (Harris et al, 1999). XO is expressed mainly 
in the endothelium, and its expression and activity are enhanced by Ang II or oscillatory 
shear in a NADPH oxidase-dependent manner (Landmesser et al, 2007).  
Mitochondrial electron transport generates SO2− as a side product of electron transport 
during oxidative phosphorylation. Most superoxide never escapes the highly reducing state 
of the mitochondrial matrix. If the SO2− generation is excessive, however, superoxide can 
escape to the intermembraneous space and cytosol via anion channels (Aon et al, 2004). 
In summary, the investigation of the sources of reactive oxygen species is essential to 
describe new pathways involved in the pathogenesis of cardiovascular diseases as well as to 
develop new therapies to treat those disorders.  
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4. ROS in the heart 
It is already known in the literature some mechanisms regarding the role of antioxidants 
during oxidative stress caused by ROS in the heart tissue. Among the enzymatic and non-
enzymatic antioxidants involved in ROS-induced heart tissue injury we may include 
catalase, glutathione, SOD, ascorbid acid, melatonin, Vitamin C and E, among others. The 
antioxidant system in SHR cardiomyopathic hearts is induced, possibly due to events of 
enhanced ROS. This conditioning of the antioxidant system may help to overcome acute 
stress situations caused by ROS in the failing myocardium (Takimoto & Kass, 2007). 
There are several potential sources of ROS in the heart with chronic heart failure (CHF). 
Excessive ROS derived from mitochondria have been shown in cardiomyocytes from 
experimental models of myocardial infarction and rapid pacing‐induced heart failure (Ide et 
al, 2001). The enzyme xanthine oxidase produces O2− as a byproduct of the terminal steps 
of purine catabolism and recent studies suggest that it collaborates to oxidative stress in 
CHF. Xanthine oxidase expression and activity are enhanced in experimental models of 
CHF as well as in human end‐stage CHF.  
Nitric oxide synthase enzymes normally generate nitric oxide, but may instead generate 
O2− if this molecule becomes “uncoupled”, a state that is mainly observed likely in the 
setting of lack of the BH4, which is a NOS cofactor or the NOS substrate l‐arginine. NOS 
uncoupling and subsequent O2− production are implicated in the genesis of vascular 
endothelial dysfunction in patients with heart failure (Dixon et al, 2003).  
In this context, infiltrating inflammatory cells are also an important source of ROS, mainly in 
conditions such as myocarditis and in the early stages after myocardial infarction. Recent 
evidence suggests that complex enzymes called NADPH oxidases are mainly important 
with regard to redox signalling in CHF and its antecedent conditions (Li et al, 2002). These 
enzymes catalyse electron transfer from NADPH to molecular oxygen, resulting in the 
formation of O2−. NADPH oxidase activity has been found to be enhanced in experimental 
models of left ventricle hypertrophy and CHF as well as in end‐stage failing human 
myocardium (Li et al, 2002).  
Interestingly, ROS produced by NADPH oxidases can promote ROS generation by other 
sources, thereby increasing total levels of ROS. For instance, O2− from NADPH oxidase may 
oxidize and degrade BH4, thereby leading to NOS uncoupling, and this mechanism has 
been shown in diabetes and experimental hypertension (Verhaar et al, 2004). Similarly, 
NADPH oxidase‐derived ROS may also activate xanthine oxidase (Li and Shah, 2004). 
Previous studies have already investigated the relationship between the regulation of 
myocardial growth and death by NADPH oxidase. The classical phagocyte oxidase 
(gp91phox or Nox2) is also expressed in non-phagocytic cells in the heart, such as 
cardiomyocytes and fibroblasts (Bendall et al, 2002; Zhang et al, 2006). Activation of Nox2 
requires stimulus-induced membrane translocation of cytosolic regulatory subunits, 
including p47phox, p67phox, p40phox, and Rac1, a small GTPase (Uhlinger et al, 1994). In 
resting cells, p47phox, p67phox, and p40phox form a ternary complex in the cytoplasm, 
whereas Rac associates with Rho-GDP dissociation inhibitor. When cells are stimulated with 
agonists for G protein-coupled receptors, such as angiotensin II (Ang II) type 1 receptors, 
p47phox is phosphorylated by protein kinase C, which in turn undergoes conformational 
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changes and allows the phox homology (PX) domain and the SH3 domain in p47phox to 
interact with phosphoinositides and p22phox in the membrane, respectively (Ago et al, 
2004). As p67phox and p40phox interact with p47phox, this process leads to membrane 
translocation of p67phox and p40phox. Rac1 translocates to the membrane independently of 
p47phox and p67phox, where they form a functional complex with the Nox2-p22phox 
heterodimer, followed by a transfer of electrons to molecular oxygen (Quinn et al, 1993). 
Therefore, the activity of Nox2 is subjected to regulation through multiple mechanisms. 
In relation to myocardial damage and NADPH oxidase, the loss of cardiomyocytes through 
apoptosis or necrosis causes impairment in cardiac function in the heart submitted to 
chronic myocardial infarction (Wencker et al, 2003). Oxidative stress is involved in the 
pathogenesis of apoptosis through various pathways, in which it is included activation of 
enzymes involved in pro-apoptotic signaling, for example, JNK, p38, ASK-1,  and CaMKII 
(Matsuzawa and Ichijo, 2005), effects on the cellular anti-apoptotic signaling and direct 
effects of ROS on mitochondria, leading to cytochrome-c release. 
Although excessive production of ROS by Noxs is detrimental, local and modest production of 
H2O2 and O2− by Noxs allows those component to function as signaling molecules, thereby 
mediating physiological responses. For instance, since Noxs are functional at low pO2, Noxs 
may function as a sensor, and ROS generated by Noxs as a transducer, for hypoxia (Shiose et 
al, 2001). Erythropoietin (EPO) synthesis occurs in the renal tubular cells, where Nox4 is 
abundantly expressed (Lacombe et al., 1988). Since DPI, an antioxidant drug, not only blocks 
oxygen sensing but also inhibits Nox4 in renal tubular cells, it has been proposed that Nox4 is 
an O2 sensor in the kidney and may regulate EPO production. The causative role of Nox4 in 
mediating EPO synthesis through its function as an O2 sensor remains to be shown. Recently, a 
role of Nox4 in mediating angiogenesis during cardiac hypertrophy was reported. 
Pathological hypertrophy induces upregulation/activation of Nox4, which in turn causes 
stabilization of HIF-1α, upregulation of VEGF, and increases in angiogenesis (Zhang et al, 
2006). It appears that the protective effect of Nox4 prevails under the authors' experimental 
conditions. It remains unknown, however, whether such a mechanism is sufficient to 
overcome increases in cell death and mitochondrial dysfunction directly caused by 
upregulation of Nox4 in response to hypertrophic stimuli (Ago et al, 2003). 
In addition, the regulation of Ca2+ level in cardiac myocytes is centrally important not only 
in excitation–contraction coupling but also in many other processes such as the regulation of 
gene expression and cellular energetics. ROS are recognized to be capable of influencing 
cellular Ca2+ regulation at several levels, notably via redox alterations of key amino acid 
residues involved in the function and gating properties of intracellular and plasma 
membrane ion channels and transporters — e.g., L-type channels, the Na+/Ca2+ exchanger, 
the sarcoplasmic reticulum (SR) ATPase (SERCA) and the ryanodine receptor (Hool and 
Corry, 2007). Recent studies have started to address the role of NADPH oxidase-derived 
ROS in these effects. 
It has been reported that ryanodine receptor-mediated Ca2+-induced Ca2+ release in rat 
cardiac myocytes is inhibited by an endogenous NADH oxidase activity in the SR, although 
the molecular nature of this oxidase was not established (Cherednichenko et al, 2004). In 
contrast to this study, Sanchez et al. (2008) reported the presence of Nox2 NADPH oxidase 
activity in canine cardiac SR and showed that oxidase activation enhanced S-
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glutathionylation of ryanodine receptors and hence SR Ca2+ release — effects which were 
abrogated by apocynin (a purported Nox inhibitor, but which may act as a non-selective 
antioxidant). The same group also showed that oxidase activity and the effects on SR Ca2+ 
release were augmented by tachycardia (Sanchez et al, 2008). O2−radical production by 
NADPH oxidase on the SR of bovine coronary artery smooth muscle cells has also been 
shown to regulate calcium-induced calcium release (Yi et al, 2006). In isolated cardiac 
myocytes, plasma L-type Ca2+ channel open-state probability was reportedly enhanced by 
endothelin-1 together with enhanced NADPH oxidase activity, effects which were abolished 
in cardiomyocytes pre-treated with a specific NADPH oxidase inhibitor, gp91ds-tat (Zeng et 
al, 2008). These studies suggest that NADPH oxidases may acutely regulate at least two 
channels directly involved in intracellular Ca2+ homeostasis, i.e. the L-type Ca2+ channel and 
the ryanodine receptor. 
In summary, Figure 3 presents the main mechanisms involved in ROS-induced 
cardiovascular disorders. Many studies implicate ROS-generating NADPH oxidases in 
redox signaling in cardiovascular cells and involvement in pathological processes such as 
cardiac hypertrophy, fibrosis, apoptosis and ventricular remodeling. 
 
Fig. 3. Main mechanisms involved in the potential effects of NADPH oxidase-derived ROS 
in the cardiac myocyte. SR: sarcoplasmic reticulum; MMPs: matrix metalloproteinases; 
CICR: calcium-induced calcium release. 
5. ROS-Induced vascular damage 
ROS are involved in pathological and physiological processes in the vasculature. Enhanced 
arterial pressure is partially caused by enhanced total peripheral vascular resistance, which 
is due to disorders of structural remodeling of blood vessels and vasomotor function. 
Vascular diseases including coronary artery disease, cerebrovascular and peripheral 
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vascular diseases are the largest cause of mortality and morbidity in industrialized 
countries. Many common risk factors for vascular disease, such as hypertension and 
diabetes, remain prevalent in Western and other populations, suggesting that vascular 
disease will continue to impose a substantial burden on health care resources throughout 
the next generation. The earliest detectable changes in vascular disease states are 
irregularities of the endothelium, resulting in loss of the endothelium normal homeostatic 
functions that normally act to inhibit disease-related processes such as inflammation and 
thrombosis. In particular, nitric oxide (NO) produced by NO synthase (eNOS) in the 
vascular endothelium modulates blood flow and pressure (Umans & Levi, 1995) and has 
important antiatherogenic effects on platelets, vascular smooth muscle and endothelial cells.  
It is known that ROS causes vascular tone increase, because it influences endothelium 
regulatory role and also due to its effects on vascular smooth muscle contractility. By 
influencing phenotype regulation of vascular smooth muscle cells, death of vascular cells, 
cell migration, atypical growth, and extracellular matrix (ECM) reorganization, ROS 
collaborate to vascular remodeling (Lee & Griendling, 2008). 
The fact that nitric oxide (NO) is scavenged by superoxide suggests that superoxide 
production may in part underlie endothelial dysfunction in human atherosclerosis, as it 
does in some experimental models of vascular disease. 
In vitro (Lambeth et al, 2000) and in vivo (Vita et al, 1990) studies indicate that ACh-
mediated vasorelaxations in human vessels are inversely related to the number of 
atherosclerotic risks factors present. Nonetheless, functional studies of human vascular 
superoxide production have been more limited (Lambeth et al, 2000). It was found large 
variability in both NO mediated vascular relaxations and basal superoxide production in 
internal mammary arteries (Huraux et al. (1999), however, there was no consistent 
associations between these two parameters or with clinical risk factors (Lambeth et al, 2000).  
It was investigated superoxide production by NAD(P)H oxidase in human vessels and the 
relationships between superoxide production, atherosclerotic risk factor profile and 
endothelial dysfunction. It was reported the expected inverse correlation between risk factor 
profile and NO-mediated endothelium-dependent relaxations in vessel ring isometric 
tension studies. However, it was also found that superoxide production by NAD(P)H 
oxidases progressively enhanced with increasing risk factor profile (Guzik et al, 2000). 
Furthermore, NAD(P)H oxidase-mediated superoxide production was inversely correlated 
with NO-mediated vasorelaxations in individual patients, such that patients with the 
highest superoxide production had the most deficient endothelial function. 
The association between enhanced vascular NAD(P)H oxidase activity and impaired 
endothelial vasorelaxations may be due to direct scavenging of NO by superoxide, as has 
been demonstrated in animal model systems. However, the both could result independently 
from increasing exposure of endothelium, media and adventitia to factors acting through 
different signaling pathways. Alternatively, superoxide may directly modulate NO-
mediated vascular signaling, for instance by peroxynitrite-induced nitration of G proteins or 
other membrane components (Feron et al, 1999). Previous data suggest that G protein-
coupled receptor function is deficient in atherosclerosis (Liao & Clark, 1995). Previous 
observation that vasorelaxations to ACh were significantly lower than maximal relaxations 
www.intechopen.com
 
Oxidative Stress and Diseases 
 
54
to the calcium ionophore A23187 is consistent with this hypothesis, and with observations in 
human internal mammary arteries (Hurax et al, 1999). Nevertheless, the significant 
correlation between ACh and A23187 - induced relaxations, and the association of NADH-
dependent superoxide production with both ACh and A231287- stimulated vasorelaxations 
suggest that a change in G protein-coupled receptor signaling is unlikely to be the sole 
mechanism underlying decreased NO-mediated vasorelaxations, as A23187 activates 
endothelial NO synthase independently of any receptor mediated pathway. Alternatively, 
superoxide may impair endothelial function by direct effects on endothelial NO synthase 
activity, (Peterson et al, 1999), possibly mediated through oxidation of the NOS cofactor, 
tetrahydrobiopterin (BH4). 
Many studies have focused on the potential role of BH4 oxidation different oxidized 
biopterin species in reducing BH4 bioavailability for eNOS (Figure 4).  
 
Fig. 4. Schematic representation of nitric oxide synthase (NO synthase) reaction leading to l-
citrulline and nitric oxide (NO) from l-arginine and oxygen (O2) without (A) and with BH4 
(B). It is important to note that this reaction without BH4 increases ROS. 
Although superoxide can indeed react directly with BH4, the rate constant of this reaction is 
many orders of magnitude lower than that for NO with superoxide (Vasquez-Vivar et al, 
2002). A more likely mechanism for BH4 oxidation is the interaction with peroxynitrite 
(generated from the interaction between NO and superoxide). It was indicated that 
peroxynitrite can oxidize BH4 within minutes at physiologically relevant concentrations 
(Crabtree et al, 2011). EPR (electron paramagnetic resonance) spectroscopy experiments 
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have demonstrated that peroxynitrite oxidizes BH4 to the (non-protonated) BH3 
(trihydrobiopterin) radical, and then to BH2, with a rate constant estimated to be 6 × 103 
M−1 s−1, several-fold higher than reactions between peroxynitrite and ascorbate, 
glutathione or thiol groups (Gao et al, 2009). Oxidation not only directly reduces BH4 
bioavailability, but the oxidation products themselves (such as BH2), which have no cofactor 
activity, may compete with BH4 for binding to endothelial NOS (eNOS) (Crabtree et al, 
2008). 
ROS are also involved in vascular remodeling. Vascular remodeling is defined as alteration 
of structure leading to alteration in wall thickness and lumen diameter. It can be induced 
through passive adaptation to chronic changes in hemodynamics and/or through 
neurohumoral factors including Ang II and ROS. The progression of hypertension involves 
two different types of vascular remodeling: inward eutrophic remodeling and hypertrophic 
remodeling (Schiffrin, 2004). Eutrophic remodeling is characterized by decreased lumen 
size, thickening of the media, enhanced media:lumen ratio and, usually, little change in 
medial cross-sectional area. In this case, the change in vascular smooth muscle (VSMC) size 
is negligible (Korsgaard et al, 1993), and medial growth toward the lumen is mainly 
mediated by reorganization of cellular and non cellular material of the existing vascular 
wall, accompanied by enhanced apoptosis in the periphery of the blood vessel (166). This is 
common in small resistance arteries of essential hypertensive patients and SHR (Korsgaard 
et al, 1993).  
On the other hand, hypertrophic remodeling characterized by an increase in wall cross-
sectional area predominates in conduit arteries of secondary hypertension, such as those of 
renovascular hypertensive patients or Ang II-infused hypertensive rats. An increase in cell 
size and enhanced accumulation of ECM proteins such as collagen and fibronectin are 
specific features of hypertrophic remodeling (Rizzoni et al, 2000). Hence, VSMC 
hypertrophy and ECM synthesis are required for hypertrophic remodeling. Both mechanical 
wall stress and humoral mediators such as Ang II collaborate to hypertrophic remodeling 
(Rizzoni et al, 2000). 
The both forms of remodeling frequently coexist in different vascular beds and at different 
stages of hypertension, which occurs even in the same subject. Even though the 
determinants of each type of remodeling have not been clearly described, the reorganization 
of media mediated by phenotype modulation of VSMCs, migration, cellular growth, 
apoptosis, and ECM production and rearrangement is thought to be common to both 
processes. These events occur cooperatively and simultaneously. 
Thus, it is not easy to distinguish contributions of each component in vivo. Vascular 
remodeling is improved by treatment with tempol, antioxidant vitamins (Chen et al, 2011), 
Ang II receptor antagonists, or NADPH oxidase inhibitors in animal experimental models, 
as well as in clinical trials (Zhou et al, 2005), emphasizing the role of ROS. 
Recent studies with improved forms of ROS scavenging enzymes, specific inhibitors for 
different ROS generating enzymes, and redox signaling pathway blocking agents allow 
subtle modulation of redox signaling and may overcome the redundancy of general 
antioxidant treatments. Therefore, the spatial and temporal aspects of redox signaling in the 
vasculature are of much importance to understand the etiological role of ROS and to 
develop better strategies to treat hypertension. 
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6. Oxidative stress in the kidney 
Renal artery obstruction can cause arterial hypertension, which is followed by impaired renal 
function and renal atrophy. Cardiovascular disorders caused by kidney injury are in part 
regulated by renin release from the stenotic kidney, with a subsequent increase in angiotensin 
II (Ang II) synthesis (Trinquart et al, 2010). Ang II results in the activation of O2− generation 
through nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a multi-subunit 
enzyme, which is one of the enzymatic sources of O2− (Chabrashvili et al, 2002). 
The mechanism(s) by which ANG II produces superoxide is not entirely elucidated yet. 
However, Mollnau et al. (2002) found that ANG II infusion during seven days enhanced 
expression of nox 1, gp91(phox), and p22(phox) subunits of NADPH oxidase via a PKC 
system. The mechanism which involves ANG II-mediated increase in the release of 
superoxide locates into activity a series of events that may play relevant functions in 
increased blood pressure. 
Previous studies were conducted in attempt to clarify the specific components of ROS that 
are involved in the development of ANG II-induced hypertension. Haas et al. (1999) are 
among the first to demonstrate that the slow hypertensive response to ANG II was 
accompanied by a significant elevation of ROS as estimated indirectly by increases in 
plasma F2-isoprostanes, an oxidative metabolite of arachidonic acid (Morrow et al, 1990). 
Nishiyama et al. (2002) also demonstrated that a prolonged infusion of ANG II in rats 
stimulates ROS production. In this study, the administration of tempol, a SOD mimetic, 
reversed the vasoconstriction and produced vasodilation via an NO-dependent mechanism.  
Ortiz et al. (2011) found in rats that the development of slow pressor responses to ANG II 
could be inhibited by the administration by antioxidants such as tempol and vitamin E. As a 
result of antioxidant treatment, there was a fall in renal blood flow and glomerular flow 
rate, whereas the indexes of oxidative stress, TBARS, and isoprostanes were found to be 
decreased in peripheral circulation as well as the renal vein. 
Some investigations suggest that the decrease in the NO concentration due to interaction 
with superoxide anon radical constitutes a major component in the development of the 
observed vasoconstriction. Supporting the assumption that inhibition of NO synthesis 
enhances the vasoconstrictor effect of ANG II are the studies of Kitamoto et al. (2000). These 
investigators found that the continuous administration of l-NAME (a NOS inhibitor) to 
Sprague-Dawley rats for seven days induced ROS production, which was dependent on 
ANG II, because the effect was blocked by the administration of ANG II receptor blockers. 
Relevant to these findings are the studies of Usui et al. (1999), who also found an increase in 
ROS produced byl-NAME, which was blocked by the administration of antioxidants. In this 
study, l-NAME blockade was associated with an increase in angiotensin converting enzyme 
activity in the aorta. The studies of Kitamoto et al. (2000) and Usui et al. (199) reveal an 
interesting aspect of ANG II, NO, and oxidative stress. They suggest that a simple decrease 
in NO synthesis leaves unbalanced ANG II, which induces ROS release. This situation will 
be further stimulated by the increase in converting enzyme activity, which can accelerate the 
production of ANG II causing a positive feedback for oxidative stress. 
The question of whether NO inhibition alone can cause ROS production without the 
participation of ANG II should be further explored. As mentioned previously, NOS can 
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produce superoxide when BH4 is oxidized to BH4, leading to an increase in ROS and a 
reduction in NO (Figure 4). This could set up a vicious cycle that accentuates NO 
dysfunction and tends to perpetuate oxidative stress. These alterations may constitute an 
important mechanism of dysregulation that produces hypertension and renal dysfunction 
(see later). An example of this alteration is the SHR in which blood pressure can be 
normalized by the administration of BH4 (McIntyre et al, 1997). 
Researches performed in the renovascular model of hypertension in rats have shown 
relevant data regarding the relationship between oxidative stress and hypertension. The 
central regulation of the sympathetic nervous system (SNS) 
involved in cardiovascular regulation is complex, involving multiple reflex pathways and 
neural connections with a large number of neurotransmitters and neuromodulators acting in 
specific groups of neurons in the central nervous sysem (CNS) involved in the tonic and 
reflex control of the cardiovascular system. In the CNS, Ang II is able to increase 
sympathetic vasomotor tone and blood pressure, and is involved in the pathogenesis of 
many experimental models of hypertension. Thus, the close functional association between 
NADPH oxidase and the Ang II is of particular relevance in linking oxidative stress in the 
brain to sympathoexcitation and hypertension (Campos, 2009). For instance, 
intracerebroventricular infusion of NADPH oxidase inhibitor antagonizes the pressor 
response induced by centrally mediated Ang II actions (Gao et al, 2004).  
In the brain, the overexpression of SOD, an enzyme responsible for O2 breakdown, also 
abolishes the central pressor effect of the octapeptide (Zimmerman et al, 2004) suggesting 
that in the CNS there is a positive correlation between the increase in ROS and the central 
pressor response mediated by Ang II. Considering that the paraventricular nucleus of the 
hypothalamus (PVN) and the rostroventrolateral medulla (RVLM) contain critically 
important neurons involved in the control of sympathetic vasomotor tone and arterial 
pressure (Colombari et al, 2001). 
Previous studies reviewed and examined whether there was an increase in AT1 receptor 
expression and oxidative stress markers within these two nuclei in 2K1C hypertension. 
NAD(P)H oxidase subunits (p47phox and gp91phox) and antioxidant enzyme CuZnSOD 
mRNA expression were quantified in the RVLM and PVN of 2K1C hypertensive rats. It was 
hypothesized that the overactivity of NADPH oxidase-derived ROS associated with a 
reduction in the activity of CuZnSOD within the RVLM and PVN could collaborate to 2K1C 
hypertension, particularly in the renin-dependent phase of hypertension. 
In summary, the recent studies support the idea that an increase in ROS in the kidney is 
involved in the development of cardiovascular disorders, playing a major role in maintaining 
high arterial pressure and sympathetic drive under conditions of renovascular hypertension. 
7. The involvement of the nervous system in ROS-induced cardiovascular 
disease 
Neurons in the brain present increased density of polyunsaturated fatty acids in its cell 
membranes. Fatty acids are targets of free radicals. An indirect marker of ROS, TBARS is 
enhanced in the brainstem of SPSHR compared to age-matched control (Hirooka, 2008). 
Others reported enhanced ROS in the brainstem of rabbits with heart failure (Gao et al, 2007).  
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The activity of sympathetic and parasympathetic systems, which are both involved in 
cardiopulmonary reflex, as well as the cardiovascular regulation, is under the control of a 
medullary circuitry comprising the nucleus of the solitary tract (NTS), rostral (RVLM) and 
caudal ventrolateral medulla (CVLM) and the nucleus ambiguous. Drugs injection into the 
fourth cerebral ventricle (4th V) may easily reach structures surrounding the ventricular 
system like the area postrema and the dorsal motor nucleus of the vagus (Colombari et al, 
2001) (Figure 5). Those areas are also involved in cardiovascular reflex responses, in which 
we may include baroreflex (Valenti et al, 2009a; Valenti et al, 2009b; Cisternas et al, 2010). 
 
Fig. 5. Schematic sagittal view of the medulla oblongata showing brain pathways implicated 
in neurogenic hypertension. Premotor neurons from the RVLM send excitatory synapses to 
preganglionic neurons situated in the intermediolateral cell column (IML), providing 
sympathetic efference to target organs. The RVLM is the group of neurons that receive 
excitatory afference from the commissural nucleus of the solitary tract (NTS) and area 
postrema. It also receives inhibitory afferences from the caudoventrolateral medulla 
(CVLM). Adapted from Valenti et al, 2007. 
A previous investigation suggested that brain ROS is associated with enhanced sympathetic 
activity (Gao et al, 2007) and systemic ROS is also related to impaired baroreflex (Bertagnolli 
et al, 2006). In addition, it was reported increase of NAD(P)H oxidase activity and 
expression into the RVLM, the primary central site for the maintenance of sympathetic 
nerve activity, in CHF rabbits. In the same sequence of procedures, the same authors 
observed that a reduction of brain O2− by tempol, a SOD mimetic, decreased the 
sympathetic outflow in chronic heart failure rabbits. Conversely, an increase of central O2− 
due to administration of the SOD inhibitor diethyldithiocarbamic acid enhanced the 
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sympathetic outflow in both normal and chronic heart failure rabbits (Gao et al, 2007). 
Taken together, those data suggest that antioxidant enzymes, i.e., SOD and catalase, into the 
brainstem are involved in baroceptor reflex regulation, since baroreflex is modulated by 
sympathetic and parasympathetic activity (Valenti et al, 2009a). 
Recent studies from our laboratory have investigated the effects of ROS into the fourth 
cerebral ventricle (4th V) on cardiovascular responses.  
In one study (Valenti et al, 2011a) it was evaluated the effects of 3-amino-1,2,4-triazole 
(ATZ), a catalase inhibitor, into the 4th V on baroreflex components in conscious rats. It was 
revealed that this drug significantly attenuated bradycardic and tachycardic reflex, 
bradycardic peak and it also decreased heart rate range 30 minutes after its injection. While 
in Wistar rats treated with vehicle (saline 0.9%) there were no significant changes regarding 
baseline mean arterial pressure (MAP) and heart rate (HR) and baroreflex components. 
Considering that the tachycardia (tachycardic reflex) in response to SNP is mediated by both 
sympathetic and parasympathetic activity (Stornetta et al, 1987) and that we reported 
reduction in the maximal parasympathetic responses to elevation in mean arterial pressure, 
while there were no changes in tachycardic peak response to decrease in mean arterial 
pressure (highest sympathetic response), we suggest that ATZ into the 4th V is acutely 
involved with parasympathetic activity but is not involved in baroreflex changes. The lack 
of any change in the vehicles groups is consistent with this assumption. In view of the 
anatomical scope of the 4th V, an action on an only one neuronal cluster is not an easy 
accomplishment. However, prior researches indicated a preference for parasympathetic 
system which modulates HR, such as the dorsal motor nucleus of the vagus and nucleus 
ambiguous, which receive glutamathergic projections from the nucleus of the solitary tract 
(Colombari et al, 2001). 
In another study (Valenti et al, 2011b), it was evaluated the effects of catalase inhibition into 
the 4th V on cardiopulmonary reflex in conscious Wistar rats. In this method, we used male 
Wistar rats, which were implanted with a stainless steel guide cannula in the 4th V. The 
femoral artery and vein were cannulated for MAP and HR measurement and for drug 
infusion, respectively. After basal mean arterial pressure and heart rate recordings, the 
cardiopulmonary reflex was tested with a dose of phenylbiguanide (PBG, 8 μg/kg, bolus). 
Cardiopulmonary reflex was evaluated before and 15 minutes after 1 μl of ATZ (0.01 g/100 
μl) injection into the 4th V. Vehicle treatment did not change cardiopulmonary reflex 
responses. ATZ injected into the 4th V significantly enhanced hypotensive responses 
without influencing the bradycardic reflex. Taken together, those data suggested that ATZ 
injected into the 4th V increases sympathetic inhibition but does not change the 
parasympathetic component of the cardiopulmonary reflex in conscious Wistar rats. 
Nevertheless, opposite findings were found in SHR. Another study (Valenti et al, 2011c) was 
undertaken to evaluate the acute effects of central n-acetylcysteine, an antioxidant drug, on 
baroreflex in juvenile SHR and age-matched Wistar Kyoto (WKY) rats. It was observed that 
n-acetylcysteine injection into the 4th V did not significantly change baroreflex gain, 
bradycardic and tachycardic reflex, bradycardic and tachycardic peak in SHR and WKY rats. 
Interestingly, n-acetylcysteine caused slight but significant increase in basal heart rate 15 
minutes after its injection in conscious WKY rats. 
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Many previous studies have already demonstrated the effects of oxidative stress in 
cardiovascular reflex. Zanzinger and  
Czachurski (2009) demonstrated that SOD injected into the RVLM decreased sympathetic 
nerve activity in swine. Several groups have now shown that ROSs stimulate sympathetic 
outflow (Campese et al, 2004). Campos et al (2011) evidenced that the lack of LDL receptor 
enhanced cholesterol blood levels, enhanced ROS and impaired baroreflex sentivity. 
Monahan et al (2007) supported the hypothesis that oxidative stress collaborates to age-
associated decreases in cardiovagal baroreflex sensitivity in healthy men. On the other hand, 
Wright et al (2009) indicated that in male smokers, circulating antioxidants had no effect on 
baroceptor reflex function and minor effects on the cardiovascular system were seen 
following acute fat and vitamin ingestion. 
In the central nervous system, the complex regulating blood pressure is contained within 
topographically selective networks characterized at all levels of the neuraxis. Adjustments in 
this modulation network may lead to labile changes in autonomic function. The 
development of neurogenic hypertension may involve improper alterations in synaptic 
function within these networks. Thus, investigations regarding the relationship between the 
nervous system and the cardiovascular system and its importance to regulation of the 
physiologic homeostasis are always welcome in the basic and clinical research. 
8. Perspectives 
At the moment, relevant milestones were achieved with the availability of more overt facts 
that demonstrates that cardiovascular disorders mechanisms are linked to ROS increase and 
dysregulation of oxidant-antioxidants systems. The oxidation and nitration of cellular lipids, 
proteins and nucleic acids, and formation of aggregates of oxidized molecules underlie the 
loss of cellular function, cellular ageing and the inability of cells to withstand physiological 
stresses. Moreover, ROS regulate energy metabolism and signal transduction mechanisms in 
response to situations of nitrosativeor or oxidative stress. Sources of ROS, physiological and 
pathophysiological conditions, and cellular oxidant targets determine the profile nature of a 
disease process and resultant outcomes.  
In summary, the data presented in this chapter is significant to the literature, because 
progress in redox signaling provides insight into the function of ROS in the pathological and 
physiological mechanisms involved in cardiovascular disorders. Nonetheless, the literature 
raises more questions. Regarding hypertension treatment, there are a few points to be 
underscored. ROS act as signaling molecules associated with diverse physiological 
mechanism which are indispensable for normal function of the brainstem. Inappropriate 
modulation of ROS impairs redox signaling, which is assumed to stimulate pathologic 
situations, in which we may include hypertension. Moreover, our study reinforces the 
importance to investigate the integrative neuroscience. 
9. Concluding remarks 
Advances in ROS signaling provide insight into the role of ROS in the pathological and 
physiological mechanisms related to cardiovascular disorders. The comprehension of how 
redox state regulates the cardiovascular system is a relevant step for a best explanation for 
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the mechanism involved in antioxidant species applied in clinical therapies. Therefore, the 
presentation of data regarding the systems different from the cardiovascular system 
implicated in ROS-induced cardiovascular diseases is relevant to the integrative physiology 
and more particularly to control physiology and clinical therapies that aim to prevent 
cardiovascular disorders such as hypertension and heart failure. 
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